We dosed the first patients in our Phase 3 program for tilrekimig, an investigational trispecific antibody discovered in @Pfizer laboratories, just months after the encouraging Phase 2 results shared earlier this year.

These three studies are the latest of many pivotal starts in an ambitious year for our R&D portfolio. A fourth Phase 2/3 study in COPD is also ongoing.

Thank you to my colleagues working at great speed on this program and to the patients and families now enrolling. I look forward to sharing more soon.